President, North America , GCI
Sherry brings over 20 years of experience in healthcare communications, spending the last several years leading GCI Group in the US.
Sherry brings a deep agency-growth mindset to the role, where she has been a leading force in GCI's tremendous growth for the past 9 years. Her fierce dedication to retaining and hiring the best people in the healthcare communications industry has lead the agency to consistently be a best agency to work for and finalist in numerous agency and campaign awards.
Sherry built her healthcare communications career focusing on US and global product milestones, issues management and flawless execution of both professional and consumer branded and disease awareness activities. Her experience is vast in the space, having lead a diverse group of large and small clients, spanning all elements of lifecycle management and company size. Her work has spanned rare diseases to conditions that impact millions of people, in the areas of oncology (solid tumors and hematology from pre-approval to mature brands), inflammation and immunology (psoriasis, rheumatoid arthritis, UC), vaccines (meningitis, HPV and COVID-19), dermatology (eczema), cardiovascular, gene therapies (various platforms), CNS (ADHD), men's health (ED) and more. Sherry also has extensive experience communicating to women, both in terms of their own health and as healthcare decision makers for the spouses and families.
Many programs that she's created and managed have won awards within the PR and marketing industry. Sherry has also led several integrated agency teams, working across marketing disciplines and agencies to provide a 360-degree approach to her clients' business for BMS, Merck, Novartis and others. What Sherry loves most about her role leading the agency and maintaining account oversight is solving for challenging situations. She takes immense pride in delivering and leading a best-in-class team to flawlessly program and execute against a challenge. Some of this work has been in competitive spaces such as the race in immuno-oncology (I-O), pricing issues with life-saving oncology medications, and market expansion in conditions requiring validations as real medical conditions including mild-to-moderate eczema and ADHD.